Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Active surveillance for low-risk bladder cancer.

Tiu A, Jenkins LC, Soloway MS.

Urol Oncol. 2014 Jan;32(1):33.e7-10. doi: 10.1016/j.urolonc.2012.12.003. Epub 2013 Mar 19. Review.

PMID:
23518309
2.

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR.

Eur Urol. 2009 Sep;56(3):430-42. doi: 10.1016/j.eururo.2009.06.028. Epub 2009 Jun 26. Review.

PMID:
19576682
3.

The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.

Karaoglu I, van der Heijden AG, Witjes JA.

World J Urol. 2014 Jun;32(3):651-9. doi: 10.1007/s00345-013-1035-1. Epub 2013 Oct 29. Review.

PMID:
24166285
4.

[EORTC risk tables--a new diagnostic tool in urology].

Bobiński J, Lipiński M.

Pol Merkur Lekarski. 2009 Dec;27(162):524-8. Review. Polish.

PMID:
20120722
5.

Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.

Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS.

Eur Urol. 2013 Sep;64(3):421-30. doi: 10.1016/j.eururo.2013.06.009. Epub 2013 Jun 19. Review.

PMID:
23830475
6.

Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.

Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ.

Eur Urol. 2012 Aug;62(2):290-302. doi: 10.1016/j.eururo.2012.05.008. Epub 2012 May 12. Review.

PMID:
22609313
7.

The economics of bladder cancer: costs and considerations of caring for this disease.

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, Lotan Y.

Eur Urol. 2014 Aug;66(2):253-62. doi: 10.1016/j.eururo.2014.01.006. Epub 2014 Jan 21. Review.

PMID:
24472711
8.

Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.

Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D, Witjes JA.

Eur Urol. 2013 Oct;64(4):624-38. doi: 10.1016/j.eururo.2013.07.007. Epub 2013 Jul 19. Review.

PMID:
23906669
9.

The role of the surgeon and transurethral resection in the treatment of superficial bladder cancer.

Nieder AM, Manoharan M.

ScientificWorldJournal. 2006 Jun 7;6:2626-31. Review.

10.

Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review.

van den Bosch S, Alfred Witjes J.

Eur Urol. 2011 Sep;60(3):493-500. doi: 10.1016/j.eururo.2011.05.045. Epub 2011 Jun 1. Review.

PMID:
21664041
11.

Management of local recurrences in the irradiated bladder: a systematic review.

Sapre N, Anderson P, Foroudi F.

BJU Int. 2012 Dec;110 Suppl 4:51-7. doi: 10.1111/j.1464-410X.2012.11476.x. Review.

12.

Contemporary management of low-risk bladder cancer.

Falke J, Witjes JA.

Nat Rev Urol. 2011 Jan;8(1):42-9. doi: 10.1038/nrurol.2010.208. Review.

PMID:
21228821
13.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Review.

PMID:
23628309
14.

Diagnosis and management of superficial bladder cancer.

Amling CL.

Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. Review.

PMID:
11514784
15.

Best approach for low-risk superficial bladder cancer.

Solsona E.

ScientificWorldJournal. 2006 Oct 23;6:2638-45. Review.

16.

[Cystoscopy in non-muscle-invasive bladder cancer: when and how (rigid or flexible)].

Cicione A, Cantiello F, Damiano R.

Urologia. 2013;80 Suppl 21:11-5. doi: 10.5301/RU.2013.10858. Epub 2013 Mar 22. Review. Italian.

PMID:
23559127
17.

Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.

Zehnder P, Thalmann GN.

Curr Opin Urol. 2013 Sep;23(5):423-8. doi: 10.1097/MOU.0b013e328363e46f. Review.

PMID:
23880740
18.

Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.

Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BW, Grossman HB, Kiemeney LA, Goebell PJ, Kamat AM.

Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29. Review.

PMID:
27368880
19.

[Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].

Werner W, Smesny S, Schubert J.

Z Arztl Fortbild Qualitatssich. 2000 Aug;94(6):519-27. Review. German.

PMID:
10996943
20.

Current management of non-muscle-invasive bladder cancer.

Rodriguez Faba O, Gaya JM, López JM, Capell M, De Gracia-Nieto AE, Gómez Correa E, Breda A, Palou J.

Minerva Med. 2013 Jun;104(3):273-86. Review.

PMID:
23748281

Supplemental Content

Support Center